Post by
Noteable on Nov 04, 2023 2:43pm
Looks Good-ONCY SITC 2023 Poster in metastatic breast cancer
November 04, 2023 - Analysis of the HR+/HER2- breast cancer tumor microenvironment (TME) following immune priming with pelareorep and atezolizumab using imaging mass cytometry - Results from the AWARE-1 trial
Pelareorep primes the TME in advance of atezolizumab administration resulting in a decline of PDL1 tumor cells after addition of Tecentriq.
The increase of PDL1 expression on day 3 and the following decrease on day 21 as seen by IHC can likely be attributed to the reduction of PDL1 positive tumor cells as a result of treatment.
https://oncolyticsbiotech.com/wp-content/uploads/2023/11/SITC_Poster_FINAL.pdf
https://www.biospace.com/article/releases/oncolytics-biotech-and-solti-present-further-positive-pelareorep-translational-data-at-sitc/
Comment by
Noteable on Nov 05, 2023 9:46am
This work further adds to the increasing evidence that pelareorep remodels an otherwise immunosuppressive TME and primes the immune system in preparation for the administration of the checkpoint inhibitor atezolizumab.